From WikiProjectMed
Jump to navigation Jump to search
Other names: Cocci, California fever, desert rheumatism, San Joaquin Valley fever[1][2]
Coccidiodes lesion 1.jpg
A skin lesion due to Coccidioides infection
SpecialtyInfectious disease[3]
SymptomsCough, fever, shortness of breath, headache, rash, muscle pain[4]
ComplicationsLong term long problems, meningitis[5][4]
Usual onset1 to 3 wks after exposure[4]
DurationWeeks to months[6]
TypesAcute, chronic[7]
Risk factorsDiabetes, pregnancy, other causes of poor immune function[8]
Diagnostic methodConfirmed by specific blood antibodies or urine antigens[5]
PreventionAvoiding dusty places, N95 facemask[8]
TreatmentNothing, antifungal medication[7]
MedicationFluconazole, amphotericin B, itraconazole[7]
Frequency~20,000 (2019 USA)[9]
Deaths200/yr (USA)[9]

Coccidioidomycosis, also known as Valley fever, is a fungal infection caused by Coccidioides.[6] Symptoms typically include cough, fever, shortness of breath, headache, rash, and muscle pain.[4] Onset is typically 1 to 3 weeks after exposure.[4] Complications may include long term long problems or meningitis.[5][4]

Specifically it is due to Coccidioides immitis or Coccidioides posadasii.[5][10] Generally infections occurs due to breathing in airborne spores after soil in which they occur is disturbed.[11] It does not typically spread between people.[8] Rarely it may spread as a result of contact with a contaminated object or organ transplantation.[11] Risk factors include diabetes, pregnancy, and other causes of poor immune function.[8] Diagnosis may be confirmed based on blood tests for specific antibodies or urine antigen tests.[5]

Most people get better without any specific treatment within weeks to months.[6] Those who are at high risk or have severe disease are generally treated with antifungal medication, with 3 to 6 months of fluconazole typically used.[5][6] Generally it occurs at most once.[8] Prevention is by avoiding dusty places or wearing an N95 facemask.[8] There is no currently available vaccine.[8]

About 20,000 cases occurred in the Southwestern United States in 2019, with the disease also being relatively common in parts of Mexico, Central, and South America.[6][9] In the United States it most commonly occurs in Arizona and California; though their are also cases in Nevada, New Mexico, Texas, Washington, and Utah.[9][11] It most commonly affects those over the age of 60.[8] It is a relatively common cause of community-acquired pneumonia in these areas.[1] In 1977, a windstorm in Arvin, California led to several hundred cases in an areas hundreds of miles away, which typically does not see the disease.[12] Other animals may also be affected.[8]

Signs and symptoms

Coccidioidomycosis skin effects

An estimated 60% of people infected with the fungi responsible for coccidioidomycosis have minimal to no symptoms, while 40% will have a range of possible clinical symptoms.[1][13] Of those who do develop symptoms, the primary infection is most often respiratory, with symptoms resembling bronchitis or pneumonia that resolve over a matter of a few weeks. In endemic regions, coccidioidomycosis is responsible for 20% of cases of community-acquired pneumonia.[13] Notable coccidioidomycosis signs and symptoms include a profound feeling of tiredness, loss of smell and taste, fever, cough, headaches, rash, muscle pain, and joint pain.[1] Fatigue can persist for many months after initial infection.[13] The classic triad of coccidioidomycosis known as "desert rheumatism" includes the combination of fever, joint pains, and erythema nodosum.[1][14]

A minority (3%-5%) of infected individuals do not recover from the initial acute infection and develop a chronic infection. This can take the form of chronic lung infection or widespread disseminated infection (affecting the tissues lining the brain, soft tissues, joints, and bone). Chronic infection is responsible for most of the morbidity and mortality. Chronic fibrocavitary disease is manifested by cough (sometimes productive of mucus), fevers, night sweats and weight loss.[13] Osteomyelitis, including involvement of the spine, and meningitis may occur months to years after initial infection. Severe lung disease may develop in HIV-infected persons.[15]


Serious complications may occur in patients who have weakened immune systems, including severe pneumonia with respiratory failure and bronchopleural fistulas requiring resection, lung nodules, and possible disseminated form, where the infection spreads throughout the body.[13] The disseminated form of coccidioidomycosis can devastate the body, causing skin ulcers, abscesses, bone lesions, swollen joints with severe pain, heart inflammation, urinary tract problems, and inflammation of the brain's lining, which can lead to death.[16]


It must rain first to start the cycle of initial growth of the fungus underneath the soil.[17] In soil (and in agar media), Coccidioides exist in filament form. It forms hyphae in both horizontal and vertical directions. Over a prolonged dry period, cells within hyphae degenerate to form alternating barrel-shaped cells (arthroconidia). Arthroconidia are light-weight and carried by air currents. This happens when the soil is disturbed often by clearing trees, construction and farming. As the population grows, so have all these industries, causing a potential cascade effect. The more land that is cleared, the more arid the soil, the riper the environment for Coccidioides.[18] These spores can be easily inhaled without the person knowing. On arriving in alveoli, they enlarge in size to become spherules, and internal septations develop. This division of cells is made possible by the optimal temperature inside the body.[19] Septations develop and form endospores within the spherule. Rupture of spherules release these endospores, which in turn repeat the cycle and spread the infection to adjacent tissues within the body of the infected individual. Nodules can form in lungs surrounding these spherules. When they rupture, they release their contents into bronchi, forming thin-walled cavities. These cavities can result in symptoms like characteristic chest pain, coughing up blood, and persistent cough. In individuals with a weakened immune system, the infection can spread through the blood. On rare occasion it can enter the body through a break in the skin, causing infection.[19]


A case of pulmonary fibrosis caused by coccidioidomycosis

Coccidioidomycosis diagnosis relies on a combination of an infected person's signs and symptoms, findings on radiographic imaging, and laboratory results.[1] The disease is commonly misdiagnosed as bacterial community-acquired pneumonia. The fungal infection can be demonstrated by microscopic detection of diagnostic cells in body fluids, exudates, sputum and biopsy tissue by methods of Papanicolaou or Grocott's methenamine silver staining. These stains can demonstrate spherules and surrounding inflammation.[20][1]

With specific nucleotide primers, C.immitis DNA can be amplified by polymerase chain reaction. It can also be detected in culture by morphological identification or by using molecular probes that hybridize with C.immitis RNA. C. immitis cannot be distinguished on cytology or by symptoms, but only by DNA PCR.[21][22]

An indirect demonstration of fungal infection can be achieved also by serologic analysis detecting fungal antigen or host IgM or IgG antibody produced against the fungus. The available tests include the tube-precipitin (TP) assays, complement fixation assays, and enzyme immunoassays. TP antibody is specific and is used as a confirmatory test, whereas ELISA is sensitive and thus used for initial testing.If the meninges are affected, CSF will show abnormally low glucose levels, an increased level of protein, and lymphocytic pleocytosis.[23][24][25][26]


After Coccidioides infection, coccidioidomycosis begins with Valley fever, which is its initial acute form. Valley fever may progress to the chronic form and then to disseminated coccidioidomycosis [27][28]

Therefore, Coccidioidomycosis may be divided into the following types:[29]


Chest X-rays rarely demonstrate nodules or cavities in the lungs, but these images commonly demonstrate lung opacification, pleural effusions, or enlargement of lymph nodes associated with the lungs.[1] Computed tomography scans of the chest are more sensitive than chest X-rays to detect these changes.[1]


Preventing Valley fever is challenging because it is difficult to avoid breathing in the fungus should it be present; however, the public health effect of the disease is essential to understand in areas where the fungus is endemic. Enhancing surveillance of coccidioidomycosis is key to preparedness in the medical field in addition to improving diagnostics for early infections.[30] Currently there are no completely effective preventive measures available for people who live or travel through Valley Fever -endemic areas. Recommended preventive measures include avoiding airborne dust or dirt, but this does not guarantee protection against infection. People in certain occupations may be advised to wear face masks.[31] The use of air filtration indoors is also helpful, in addition to keeping skin injuries clean and covered to avoid skin infection[32]

In 1998-2011, there were 111,117 cases of coccidioidomycosis in the U.S. that were logged into the National Notifiable Diseases Surveillance System (NNDSS).[33] Since many U.S. states do not require reporting of coccidioidomycosis, the actual numbers can be higher. The United States' Centers for Disease Control and Prevention (CDC) called the disease a "silent epidemic" and acknowledged that there is no proven anticoccidioidal vaccine available.[34] Studies done in the past show that the cost benefit of a vaccine is most notable among infants, teens, and immigrant adults, with negative cost-benefit results among older age groups.[35]

Raising both surveillance and awareness of the disease while medical researchers are developing a human vaccine can positively contribute towards prevention efforts.[36][37] Research demonstrates that patients from endemic areas who are aware of the disease are most likely to request diagnostic testing for coccidioidomycosis.[38] Presently, Meridian Bioscience manufactures the so-called EIA test to diagnose the Valley fever, which however is known for producing a fair quantity of false positives. Currently, recommended prevention measures can include type-of-exposure-based respirator protection for persons engaged in agriculture, construction and others working outdoors in endemic areas.[39][40] Dust control measures such as planting grass and wetting the soil, and also limiting exposure to dust storms are advisable for residential areas in endemic regions.[41]


Fluconazole (package)

Significant disease develops in fewer than 5% of those infected and typically occurs in those with a weakened immune system.[42] Mild asymptomatic cases often do not require any treatment. Those with severe symptoms may benefit from antifungal therapy, which requires 3–6 months or more of treatment depending on the response to the treatment.[43]

On the whole, oral fluconazole and intravenous amphotericin B are used in progressive or disseminated disease, or in immunocompromised individuals.[42] Amphotericin B used to be the only available treatment,[30] although now there are alternatives, including itraconazole or ketoconazole, that may be used for milder disease.[44] Fluconazole is the preferred medication for coccidioidal meningitis, due to its penetration into CSF.[10] Intrathecal or intraventricular amphotericin B therapy is used if infection persists after fluconazole treatment.[42] Itraconazole is used for cases that involve treatment of infected person's bones and joints. The antifungal medications posaconazole and voriconazole have also been used to treat coccidioidomycosis. Because the symptoms of coccidioidomycosis are similar to the common flu, pneumonia, and other respiratory diseases, it is important for public health professionals to be aware of the rise of coccidioidomycosis and the specifics of diagnosis. Greyhound dogs often get coccidioidomycosis as well, and their treatment regimen involves 6–12 months of ketoconazole, to be taken with food.[45]


Conventional amphotericin B desoxycholate (AmB: used since the 1950s as a primary agent) is known to be associated with increased drug-induced nephrotoxicity (kidney toxicity) impairing kidney function.[46] Other formulations have been developed such as lipid soluble formulations to mitigate such side-effects as direct proximal and distal tubular cytotoxicity. These include liposomal amphotericin B, amphotericin B lipid complex such as Abelcet (brand) amphotericin B phospholipid complex[47] also as AmBisome Intravenous,[48] or Amphotec Intravenous (Generic; Amphotericin B Cholesteryl Sul),[49] and amphotericin B colloidal dispersion, all shown to exhibit a decrease in nephrotoxicity. The latter was not as effective in one study as amphotericin B desoxycholate which had a 50% murine morbidity rate versus zero for the AmB colloidal dispersion.[50]

The cost of AmB deoxycholate, in 2015, for a patient of 70 kilograms (150 lb) at 1 mg/kg/day dosage, was approximately $63.80, compared to 5 mg/kg/day of liposomal AmB at $1318.80, making the less toxic option less accessible.[51]


Estimated areas with coccidioidomycosis worldwide

Coccidioidomycosis is relatively common in the western hemisphere between 40°N and 40°S. The ecological niches are characterized by hot summers and mild winters with an annual rainfall of 10–50 cm.[52] The species are found in alkaline sandy soil, below the surface. In harmony with the mycelium life cycle, incidence increases with periods of dryness after a rainy season. While the majority of cases are observed in the endemic region, cases reported outside the area are generally visitors.[53][54][55]

North America

In the United States, C. Immitis is endemic to southern and central California with the highest presence in the San Joaquin Valley. C. posadassi is most prevalent in Arizona, although it can be found in a wider region spanning from Utah, New Mexico, Texas, and Nevada. An estimated 150,000 infections occur annually, with 25,000 new infections occurring every year. The incidence of coccidioidomycosis in the United States in 2011 (42.6 per 100,000) was almost ten times higher than the incidence reported in 1998 (5.3 per 100,000). In area where it is most prevalent, the infection rate is 2-4%.[56]

Incidence varies widely across the west and southwest. In Arizona, for instance, in 2007, there were 3,450 cases in Maricopa County, which in 2007 had an estimated population of 3,880,181[57] for an incidence of approximately 1 in 1,125.[58] In contrast, though southern New Mexico is considered an endemic region, there were 35 cases in the entire state in 2008 and 23 in 2007,[58] in a region that had an estimated 2008 population of 1,984,356,[59] for an incidence of approximately 1 in 56,695.Infection rates vary greatly by county, and although population density is important, so are other factors that have not been proven yet. Greater construction activity may disturb spores in the soil.[60]

In California from 2000 to 2007, there were 16,970 reported cases (5.9 per 100,000 people) and 752 deaths of the 8,657 people hospitalized. The highest incidence was in the San Joaquin Valley with 76% of the 16,970 cases (12,855) occurring in the area.[61] Following the 1994 Northridge earthquake, there was a sudden increase of cases in the areas affected by the quake, at a pace of over 10 times baseline.[62]

There was an outbreak in the summer of 2001 in Colorado, away from where the disease was considered endemic. A group of archeologists visited Dinosaur National Monument, and eight members of the crew, along with two National Park Service workers were diagnosed with Valley fever.[63]

California state prisons, beginning in 1919, have been particularly affected by coccidioidomycosis. In 2005 and 2006, the Pleasant Valley State Prison near Coalinga and Avenal State Prison near Avenal on the western side of the San Joaquin Valley had the highest incidence in 2005, of at least 3,000 per 100,000.[64] The receiver appointed in Plata v. Schwarzenegger issued an order in May 2013 requiring relocation of vulnerable populations in those prisons.[65] The incidence rate has been increasing, with rates as high as 7% during 2006-2010. The cost of care and treatment is $23 million in California prisons. A lawsuit was filed against the state in 2014 on behalf of 58 inmates stating that the Avenal and Pleasant valley state prisons did not take necessary steps to prevent infections.[66]

Population factors

There are several populations that have a higher risk for contracting coccidioidomycosis and developing the advanced disseminated version of the disease. Populations with exposure to the airborne arthroconidia working in agriculture and construction have a higher risk. Outbreaks have also been linked to earthquakes, windstorms and military training exercises where the ground is disturbed.[52] Historically, an infection is more likely to occur in males than females.[67]

Women who are pregnant and immediately postpartum are at a high risk of infection and dissemination. There is also an association between stage of pregnancy and severity of the disease, with third trimester women being more likely to develop dissemination. Presumably this is related to highly elevated hormonal levels, which stimulate growth and maturation of spherules and subsequent release of endospores.[68] Certain ethnic populations are more susceptible to disseminated coccidioidomycosis. The risk of dissemination is 175 times greater in Filipinos and 10 times greater in African Americans than non-Hispanic whites.[69] Individuals with a weakened immune system are also more susceptible to the disease. In particular, individuals with HIV and diseases that impair T-cell function. Individuals with pre-existing conditions such as diabetes are also at a higher risk. Age also affects the severity of the disease, with more than one-third of deaths being in the 65-84 age group.[70][71]


Dr Alejandro Posadas

The first case of what was later named coccidioidomycosis was described in 1892 in Buenos Aires by Alejandro Posadas, a medical intern at the Hospital de Clínicas "José de San Martín".[72] Posadas established an infectious character of the disease after being able to transfer it in laboratory conditions to lab animals.[73] In the U.S., Dr. E. Rixford, a physician from a San Francisco hospital, and T. C. Gilchrist, a pathologist at Johns Hopkins Medical School, became early pioneers of clinical studies of the infection.[74] They decided that the causative organism was a Coccidia-type protozoan and named it Coccidioides immitis.[75]

Dr. William Ophüls, a professor at Stanford University Hospital (San Francisco), discovered[76] that the causative agent of the disease that was at first called Coccidioides infection and later coccidioidomycosis[77] was a fungal pathogen, and coccidioidomycosis was also distinguished from Histoplasmosis and Blastomycosis. Further, Coccidioides immitis was identified as the culprit of respiratory disorders previously called San Joaquin Valley fever, desert fever, and Valley fever, and a serum precipitin test was developed by Charles E. Smith that was able to detect an acute form of the infection. In retrospect, Smith played a major role in both medical research and raising awareness about coccidioidomycosis, especially when he became dean of the School of Public Health at the University of California at Berkeley in 1951.[78]

Coccidioides immitis was considered by the United States during a time period as a potential biological weapon. The strain selected for investigation was designated with the military symbol OC, and initial expectations were for its deployment as a human incapacitant. Medical research suggested that OC might have had some lethal effects on the populace, and Coccidioides immitis started to be classified by the authorities as a threat to public health. However, Coccidioides immitis was never weaponized to the public's knowledge.[79][80][81]

Currently, it is not on the U.S. Department of Health and Human Services'[82] or Centers for Disease Control and Prevention's[83] list of select agents and toxins.In 2002, Coccidioides posadasii was identified as genetically distinct from Coccidioides immitis despite their morphologic similarities and can also cause coccidioidomycosis.[84]

Other animals

A dog with coccidioidomycosis

An animal infected with Valley fever cannot transmit the disease to other animals. In dogs, the most common symptom of coccidioidomycosis is a chronic cough, which can be dry or moist. Other symptoms include fever (in approximately 50% of cases), weight loss, anorexia, lethargy, and depression. The disease can disseminate throughout the dog's body, most commonly causing osteomyelitis (infection of the bone), which leads to lameness. Dissemination can cause other symptoms, depending on which organs are infected. If the fungus infects the heart or pericardium, it can cause heart failure and death.[85]

In cats, symptoms may include skin lesions, fever, and loss of appetite, with skin lesions being the most common.[86]

Other species in which Valley fever has been found include livestock such as cattle and horses; llamas; marine mammals, including sea otters; zoo animals such as monkeys and apes, kangaroos, tigers, etc.; and wildlife native to the geographic area where the fungus is found, such as cougars, skunks, and javelinas.[87]


As of 2013, there is no vaccine available to prevent infection with Coccidioides immitis or Coccidioides posadasii, but efforts to develop such a vaccine are underway.[88][89]

A 2022 review by Galgiani, et al indicates a "live-attenuated Δcps1 vaccine has emerged as a potentially safe and effective candidate".[90]


  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Malo J, Luraschi-Monjagatta C, Wolk DM, Thompson R, Hage CA, Knox KS (February 2014). "Update on the diagnosis of pulmonary coccidioidomycosis". Annals of the American Thoracic Society. 11 (2): 243–53. doi:10.1513/AnnalsATS.201308-286FR. PMID 24575994.
  2. Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 978-1-4160-2999-1.
  3. "ICD-11 - ICD-11 for Mortality and Morbidity Statistics". Archived from the original on 1 August 2018. Retrieved 17 June 2021.
  4. 4.0 4.1 4.2 4.3 4.4 4.5 "Symptoms of Valley Fever | Coccidioidomycosis | Types of Fungal Diseases | Fungal | CDC". 13 January 2021. Archived from the original on 6 June 2020. Retrieved 22 December 2022.
  5. 5.0 5.1 5.2 5.3 5.4 5.5 "Information for Healthcare Professionals | Coccidioidomycosis | Types of Fungal Diseases | Fungal | CDC". 12 July 2021. Archived from the original on 7 October 2022. Retrieved 22 December 2022.
  6. 6.0 6.1 6.2 6.3 6.4 6.5 "Valley Fever (Coccidioidomycosis) | Types of Fungal Diseases | Fungal | CDC". 3 February 2021. Archived from the original on 29 May 2021. Retrieved 22 December 2022.
  7. 7.0 7.1 7.2 Proia, Laurie (2020). "28. The dimorphic mycoses". In Spec, Andrej; Escota, Gerome V.; Chrisler, Courtney; Davies, Bethany (eds.). Comprehensive Review of Infectious Diseases. Elsevier. pp. 418–419. ISBN 978-0-323-56866-1. Archived from the original on 2021-07-15. Retrieved 2021-07-12.
  8. 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 "Valley Fever Risk & Prevention | Types of Fungal Diseases | Fungal | CDC". 11 July 2022. Archived from the original on 30 November 2022. Retrieved 22 December 2022.
  9. 9.0 9.1 9.2 9.3 "Valley Fever Statistics | Coccidioidomycosis | Types of Fungal Diseases | Fungal | CDC". 18 July 2022. Archived from the original on 30 October 2022. Retrieved 22 December 2022.
  10. 10.0 10.1 Nguyen C, Barker BM, Hoover S, Nix DE, Ampel NM, Frelinger JA, Orbach MJ, Galgiani JN (July 2013). "Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis". Clin Microbiol Rev. 26 (3): 505–25. doi:10.1128/CMR.00005-13. PMC 3719491. PMID 23824371.
  11. 11.0 11.1 11.2 "Where Valley Fever Comes From | Coccidioidomycosis | Types of Fungal Diseases | Fungal | CDC". 10 August 2021. Archived from the original on 22 September 2022. Retrieved 22 December 2022.
  12. Pappagianis, Demosthenes; Einstein, Hans (1978-12-01). "Tempest From Tehachapi Takes Toll or Coccidioides Conveyed Aloft and Afar". Western Journal of Medicine. 129 (6): 527–530. ISSN 0093-0415. PMC 1238466. PMID 735056.
  13. 13.0 13.1 13.2 13.3 13.4 Twarog, Meryl; Thompson, George (2015-09-23). "Coccidioidomycosis: Recent Updates". Seminars in Respiratory and Critical Care Medicine. 36 (5): 746–755. doi:10.1055/s-0035-1562900. PMID 26398540. Archived from the original on 2020-06-13. Retrieved 2021-06-02.
  14. Johnstone, Ronald B. (2017). "25. Mycoses and Algal infections". Weedon's Skin Pathology Essentials (2nd ed.). Elsevier. p. 450. ISBN 978-0-7020-6830-0. Archived from the original on 2021-05-25. Retrieved 2021-06-02.
  15. Ampel N (2005). "Coccidioidomycosis in persons infected with HIV type 1". Clin Infect Dis. 41 (8): 1174–8. doi:10.1086/444502. PMID 16163637.
  16. Galgiani J. N. Coccidioidomycosis. In: Cecil, Russell L., Lee Goldman, and D. A. Ausiello. Cecil Medicine. Philadelphia: Saunders Elsevier, 2007.
  17. Kolivras K., Comrie A. (2003). "Modeling valley fever (coccidioidomycosis) incidence on the basis of climate conditions". International Journal of Biometeorology. 47 (2): 87–101. Bibcode:2003IJBm...47...87K. doi:10.1007/s00484-002-0155-x. PMID 12647095. S2CID 23498844.
  18. "Mayo Clinic". Valley Fever. Mayo Clinic. May 27, 2015. Archived from the original on October 9, 2015. Retrieved September 30, 2015.
  19. 19.0 19.1 "CDC". Fungal diseases: valley fever. CDC. July 20, 2015. Archived from the original on October 5, 2015. Retrieved September 30, 2015.
  20. "Diagnosis and testing | Coccidioidomycosis | Types of Fungal Diseases | Fungal |". 29 January 2021. Archived from the original on 20 October 2022. Retrieved 30 November 2022.
  21. Bialek, Ralf; González, Gloria M.; Begerow, Dominik; Zelck, Ulrike E. (September 2005). "Coccidioidomycosis and blastomycosis: Advances in molecular diagnosis". FEMS Immunology & Medical Microbiology. 45 (3): 355–360. doi:10.1016/j.femsim.2005.05.011. Archived from the original on 13 June 2018. Retrieved 2 December 2022.
  22. Johnson, Suzanne M.; Simmons, Keira A.; Pappagianis, Demosthenes (May 2004). "Amplification of coccidioidal DNA in clinical specimens by PCR". Journal of Clinical Microbiology. 42 (5): 1982–1985. doi:10.1128/JCM.42.5.1982-1985.2004. ISSN 0095-1137. Archived from the original on 18 June 2022. Retrieved 8 December 2022.
  23. Pappagianis, D.; Zimmer, B. L. (July 1990). "Serology of coccidioidomycosis". Clinical Microbiology Reviews. 3 (3): 247–268. doi:10.1128/CMR.3.3.247. ISSN 0893-8512. Archived from the original on 15 June 2022. Retrieved 3 December 2022.
  24. "Information for Healthcare Professionals | Coccidioidomycosis | Types of Fungal Diseases | Fungal | CDC". 12 July 2021. Archived from the original on 7 October 2022. Retrieved 5 December 2022.
  25. Peng, Tao; Zong, Yue; Johnson, Michael DL; Menghani, Sanjay V.; Lewis, Maria Lourdes; Galgiani, John N (1 January 2021). "A quantitative enzyme-linked immunoassay (ELISA) to approximate complement-fixing antibody titers in serum from patients with coccidioidomycosis". Diagnostic Microbiology and Infectious Disease. 99 (1): 115198. doi:10.1016/j.diagmicrobio.2020.115198. ISSN 0732-8893. Retrieved 9 December 2022.
  26. Scott, Pamela (10 January 2011). Cases in Clinical Medicine. Jones & Bartlett Publishers. p. 80. ISBN 978-0-7637-7180-5. Archived from the original on 10 December 2022. Retrieved 10 December 2022.
  27. "Valley Fever Awareness". Centers for Disease Control and Prevention. 22 August 2022. Archived from the original on 2 November 2022. Retrieved 1 December 2022.
  28. Twarog, Meryl; Thompson, George R. (October 2015). "Coccidioidomycosis: Recent Updates". Seminars in Respiratory and Critical Care Medicine. 36 (5): 746–755. doi:10.1055/s-0035-1562900. ISSN 1098-9048. Archived from the original on 30 November 2022. Retrieved 7 December 2022.
  29. James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 978-0-7216-2921-6.
  30. 30.0 30.1 Hector, Richard F.; Rutherford, George W.; Tsang, Clarisse A.; Erhart, Laura M.; McCotter, Orion; Anderson, Shoana M.; Komatsu, Kenneth; Tabnak, Farzaneh; Vugia, Duc J. (2011-04-01). "The Public Health Impact of Coccidioidomycosis in Arizona and California". International Journal of Environmental Research and Public Health. 8 (4): 1150–1173. doi:10.3390/ijerph8041150. ISSN 1661-7827. PMC 3118883. PMID 21695034.
  31. "Risk factors". Valley Fever Center for Excellence. Archived from the original on 2021-06-19. Retrieved 2021-06-02.
  32. "Valley Fever Risk & Prevention | Types of Fungal Diseases | Fungal | CDC". 11 July 2022. Archived from the original on 30 November 2022. Retrieved 4 December 2022.
  33. "Increase in Reported Coccidioidomycosis—United States, 1998–2011". Morbidity and Mortality Weekly Report (MMWR). Centers for Disease Control and Prevention. Archived from the original on 26 July 2013. Retrieved 6 July 2013.
  34. "Valley Fever: Awareness is Key". CDC Features. Centers for Disease Control and Prevention. Archived from the original on 7 July 2013. Retrieved 6 July 2013.
  35. Barnato, A. E.; Sanders, G. D.; Owens, D. K. (2001-01-01). "Cost-effectiveness of a potential vaccine for Coccidioides immitis". Emerging Infectious Diseases. 7 (5): 797–806. doi:10.3201/eid0705.010005. ISSN 1080-6040. PMC 2631863. PMID 11747691.
  36. Cole G.T.; Xue J.M.; Okeke C.N.; at al. (June 2004). "A vaccine against coccidioidomycosis is justified and attainable". Medical Mycology. 42 (3): 189–216. doi:10.1080/13693780410001687349. PMID 15283234.
  37. "Valley Fever Vaccine Project" (PDF). Archived from the original (PDF) on February 1, 2014. Retrieved 11 July 2013.
  38. Tsang C.A.; Anderson S.M.; Imholte S.B.; et al. (2010). "Enhanced surveillance of coccidioidomycosis, Arizona, USA, 2007–2008". Emerging Infectious Diseases. 16 (11): 1738–44. doi:10.3201/eid1611.100475. PMC 3294516. PMID 21029532.
  39. Das R.; McNary J.; Fitzsimmons K.; et al. (May 2012). "Occupational coccidioidomycosis in California: outbreak investigation, respirator recommendations, and surveillance findings". Journal of Occupational and Environmental Medicine. 54 (5): 564–571. doi:10.1097/JOM.0b013e3182480556. PMID 22504958. S2CID 21931825.
  40. "Coccidioidomycosis (Valley Fever)". Health Information: Diseases & Conditions. California Department of Public Health. Archived from the original on 2013-07-08. Retrieved 11 July 2013.
  41. "Coccidioidomycosis: Prevention" (PDF). Acute Communicable Disease Control Annual Morbidity Reports, Los Angeles County, 2002-2010. Archived (PDF) from the original on 5 July 2013. Retrieved 12 July 2013.
  42. 42.0 42.1 42.2 Welsh O.; Vera-Cabrera L.; Rendon A. (November–December 2012). "Coccidioidomycosis". Clinics in Dermatology. 30 (6): 573–591. doi:10.1016/j.clindermatol.2012.01.003. PMID 23068145.
  43. Galgiani, John N.; Ampel, Neil M.; Blair, Janis E.; Catanzaro, Antonino; Geertsma, Francesca; Hoover, Susan E.; Johnson, Royce H.; Kusne, Shimon; Lisse, Jeffrey; MacDonald, Joel D.; Meyerson, Shari L.; Raksin, Patricia B.; Siever, John; Stevens, David A.; Sunenshine, Rebecca; Theodore, Nicholas (15 September 2016). "2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis". Clinical Infectious Diseases. 63 (6): e112–e146. doi:10.1093/cid/ciw360. PMID 27470238.
  44. Barron MA, Madinger NE (November 18, 2008). "Opportunistic Fungal Infections, Part 3: Cryptococcosis, Histoplasmosis, Coccidioidomycosis, and Emerging Mould Infections". Infections in Medicine. Archived from the original on March 14, 2010. Retrieved June 2, 2021.
  45. Rubensohn, Mark; Stack, Suzanne (2003-02-01). "Coccidioidomycosis in a dog". Canadian Veterinary Journal. 44 (2): 159–160. ISSN 0008-5286. PMC 340059. PMID 12650050.
  46. Drug-Induced Nephrotoxicity Archived 2021-08-28 at the Wayback Machine: American Family Physician (2008 Sep 15;78(6):743-750)- Retrieved 2017-01-16
  47. amphotericin B phospholipid complex Archived 2021-01-28 at the Wayback Machine: Medscape- Retrieved 2017-01-16
  48. AmBisome Intravenous Archived 2021-05-22 at the Wayback Machine: WebMD - Retrieved 2017-01-16
  49. Amphotec Intravenous Archived 2020-08-03 at the Wayback Machine: WebMD -Retrieved 2017-01-16
  50. AmB colloidal versus AmB deoxycholate Archived 2018-06-16 at the Wayback Machine: ResearchGate; Antimicrobial Agents and Chemotherapy 35(9):1829-33 · October 1991 (printed from PubMed)- Retrieved 2017-01-17
  51. Juan Pablo Botero Aguirre (2015). "Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function". Cochrane Database of Systematic Reviews (11): CD010481. doi:10.1002/14651858.CD010481.pub2. PMID 26595825.
  52. 52.0 52.1 Brown, Jennifer (2013). "Coccidioidomycosis: epidemiology". Clin Epidemiol. 5: 185–97. doi:10.2147/CLEP.S34434. PMC 3702223. PMID 23843703.
  53. Johnson, Royce H.; Sharma, Rupam; Kuran, Rasha; Fong, Isabel; Heidari, Arash (February 2021). "Coccidioidomycosis: a review". Journal of Investigative Medicine: The Official Publication of the American Federation for Clinical Research. 69 (2): 316–323. doi:10.1136/jim-2020-001655. ISSN 1708-8267. PMC 7848065. PMID 33495302.
  54. McCotter, Orion Z; Benedict, Kaitlin; Engelthaler, David M; Komatsu, Ken; Lucas, Kimberley D; Mohle-Boetani, Janet C; Oltean, Hanna; Vugia, Duc; Chiller, Tom M; Sondermeyer Cooksey, Gail L; Nguyen, Alyssa; Roe, Chandler C; Wheeler, Charlotte; Sunenshine, Rebecca (1 February 2019). "Update on the Epidemiology of coccidioidomycosis in the United States". Medical Mycology. 57 (Supplement_1): S30–S40. doi:10.1093/mmy/myy095. Archived from the original on 26 February 2022. Retrieved 5 December 2022.
  55. Hector, Richard F; Laniado-Laborin, Rafael (2005). "Coccidioidomycosis—A Fungal Disease of the Americas". PLoS Medicine. 2 (1): e2. doi:10.1371/journal.pmed.0020002. ISSN 1549-1277. Archived from the original on 20 October 2022. Retrieved 12 December 2022.
  56. Hospenthal, Duane. "Coccidioidomycosis". Medscape. Archived from the original on 2015-10-22. Retrieved 2015-10-18.
  57. U.S. Census Bureau, State & County QuickFacts Archived February 26, 2016, at the Wayback Machine
  58. 58.0 58.1 "Number of Reported Cases of Selected Notifiable Diseases by Category for each County, Arizona, 2007" (PDF). Arizona Department of Health Services. Archived (PDF) from the original on 21 September 2013. Retrieved 10 July 2013.
  59. New Mexico Intercensal Population Estimates from the U.S. Census Bureau "New Mexico Intercensal Population Estimates". Archived from the original on 2012-02-22. Retrieved 2016-02-07.
  60. Nicas, Mark (January 2018). "A point-source outbreak of Coccidioidomycosis among a highway construction crew". Journal of Occupational and Environmental Hygiene. 15 (1): 57–62. doi:10.1080/15459624.2017.1383612. ISSN 1545-9632. Archived from the original on 4 December 2022. Retrieved 4 December 2022.
  61. Centers for Disease Control Prevention (CDC) (February 13, 2009). "Increase in Coccidioidomycosis: California, 2000-2007". Morbidity and Mortality Weekly Report. 58 (5): 105–109. PMID 19214158. Archived from the original on May 8, 2021. Retrieved June 2, 2021.
  62. "Coccidioidmycosis Outbreak". USGS Landslide Hazards Program. Archived from the original on 2014-02-02.
  63. "Coccidioidomycosis in Workers at an Archeologic Site ---Dinosaur National Monument, Utah, June--July 2001". Morbidity and Mortality Weekly Report (MMWR), 50(45), p. 1005-1008. Centers for Disease Control and Prevention (CDC). November 16, 2001. Archived from the original on 5 July 2013. Retrieved 10 July 2013.
  64. Pappagianis, Demosthenes; Coccidioidomycosis Serology Laboratory (September 2007). "Coccidioidomycosis in California State Correctional Institutions". Annals of the New York Academy of Sciences. 1111 (1): 103–11. Bibcode:2007NYASA1111..103P. doi:10.1196/annals.1406.011. PMID 17332089. S2CID 29147634.
  65. Rachel Cook; Rebecca Plevin (May 7, 2013). "Some Prison Inmates to Be Moved Out of Valley Fever Hot Spots". Voice of OC. Archived from the original on December 23, 2013. Retrieved May 9, 2013.
  66. "CDC Says Calif. Inmates Should Be Tested for Valley Fever Immunity". California HealthLine. 2014-07-28. Archived from the original on 2016-01-04. Retrieved 2021-06-02.
  67. Smith, Dallas J. (2022). "Surveillance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis — United States, 2019". MMWR. Surveillance Summaries. doi:10.15585/mmwr.ss7107a1. Archived from the original on 29 November 2022. Retrieved 2 December 2022.
  68. Shehab, Ziad M. (2010). "Coccidioidomycosis". Advances in Pediatrics. 57 (1): 269–286. doi:10.1016/j.yapd.2010.08.008. PMID 21056742.
  69. Hospenthal, Duane (2019-01-04). "Coccidioidomycosis". Medscape. Archived from the original on 2015-10-22. Retrieved 2021-06-02.
  70. Cook, Rachel. "Just One Breath: More People Dying from Valley Fever – Especially Those With Chronic Disease, Study Shows". Reporting on Health. Archived from the original on 2015-07-12. Retrieved 2021-06-02.
  71. "Coccidioidomycosis | NIH". Archived from the original on 9 August 2022. Retrieved 2 December 2022.
  72. Posadas A. Un nuevo caso de micosis fungoidea con posrospemias. Annales Cir. Med. Argent. (1892), Volume 15, p. 585-597.
  73. Hirschmann, Jan V. (2007). "The Early History of Coccidioidomycosis: 1892–1945". Clinical Infectious Diseases. 44 (9): 1202–1207. doi:10.1086/513202. PMID 17407039.
  74. Rixford E., Gilchrist T. C. Two cases of protozoan (coccidioidal) infection of the skin and other organs. Johns Hopkins Hosp Rep 1896; 10:209-268.
  75. "Etymologia: Coccidioides - Volume 21, Number 6—June 2015 - Emerging Infectious Diseases journal - CDC". CDC. doi:10.3201/eid2106.et2106. Archived from the original on 14 September 2022. Retrieved 6 December 2022.
  76. Hirschmann, Jan (1 May 2007). "The Early History of Coccidioidomycosis: 1892–1945". Clinical Infectious Diseases. 44 (9): 1202–07. doi:10.1086/513202. PMID 17407039.
  77. Dickson, EC; Gifford, MA (1 November 1938). "Coccidioides infection (coccidioidomycosis). ii. The primary type of infection". Archives of Internal Medicine. 62 (5): 853–71. doi:10.1001/archinte.1938.00180160132011.
  78. Smith, CE (Jun 1940). "Epidemiology of Acute Coccidioidomycosis with Erythema Nodosum ("San Joaquin" or "Valley Fever")". American Journal of Public Health and the Nation's Health. 30 (6): 600–11. doi:10.2105/AJPH.30.6.600. PMC 1530901. PMID 18015234.
  79. Deresinski, Stan (September 2003). "Coccidioides immitis as a potential bioweapon". Seminars in Respiratory Infections. 18 (3): 216–219. ISSN 0882-0546. Archived from the original on 9 March 2022. Retrieved 4 December 2022.
  80. Ciottone, Gregory R. Disaster Medicine. Philadelphia, PA: Mosby Elsevier, 2006, pp. 726-128.
  81. Ciottone, Gregory R.; Biddinger, Paul D.; Darling, Robert G.; Fares, Saleh; Keim, Mark E.; Molloy, Michael S.; Suner, Selim (24 September 2015). Ciottone's Disaster Medicine E-Book. Elsevier Health Sciences. p. 813. ISBN 978-0-323-35846-0. Archived from the original on 13 December 2022. Retrieved 13 December 2022.
  82. "HHS select agents and toxins" (PDF). Code of Federal Regulations (CFR), Title 42 - Public Health. Office of the Federal Register. Archived from the original (PDF) on October 20, 2013. Retrieved 11 July 2013.
  83. "Select Agents and Toxins List" (PDF). CDC. December 4, 2012. Archived from the original (PDF) on February 28, 2013. Retrieved 11 July 2013.
  84. Fisher, M. C.; Koenig, G. L.; White, T. J. & Taylor, J. W (2002). "Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of Coccidioides immitis" (PDF). Mycologia. 94 (1): 73–84. doi:10.2307/3761847. hdl:10044/1/4213. JSTOR 3761847. PMID 21156479. Archived (PDF) from the original on 2016-01-04. Retrieved 2021-06-02.
  85. Graupmann-Kuzma, Angela; Valentine, Beth A.; Shubitz, Lisa F.; Dial, Sharon M.; Watrous, Barbara; Tornquist, Susan J. (2008-09-01). "Coccidioidomycosis in Dogs and Cats: A Review". Journal of the American Animal Hospital Association. 44 (5): 226–235. doi:10.5326/0440226. ISSN 0587-2871. PMID 18762558.
  86. Greene, Russell T.; Troy, Gregory C. (1995-03-01). "Coccidioidomycosis in 48 Cats: A Retrospective Study (1984–1993)". Journal of Veterinary Internal Medicine. 9 (2): 86–91. doi:10.1111/j.1939-1676.1995.tb03277.x. ISSN 1939-1676. PMID 7760314.
  87. "Valley Fever Center for Excellence: Valley Fever in Other Animal Species". University of Arizona. Archived from the original on 2021-06-19. Retrieved 2021-06-02.
  88. Yoon HJ, Clemons KV (July 2013). "Vaccines against Coccidioides". Korean Journal of Internal Medicine. 28 (4): 403–7. doi:10.3904/kjim.2013.28.4.403. PMC 3712146. PMID 23864796.
  89. Kirkland, Theo (2016-12-16). "The Quest for a Vaccine Against Coccidioidomycosis: A Neglected Disease of the Americas". Journal of Fungi. 2 (4): 34. doi:10.3390/jof2040034. ISSN 2309-608X. PMC 5715932. PMID 29376949.
  90. Galgiani, John N.; Shubitz, Lisa F.; Orbach, Marc J.; Mandel, M. Alejandra; Powell, Daniel A.; Klein, Bruce S.; Robb, Edward J.; Ohkura, Mana; Seka, Devin J.; Tomasiak, Thomas M.; Monath, Thomas P. (10 August 2022). "Vaccines to Prevent Coccidioidomycosis: A Gene-Deletion Mutant of Coccidioides Posadasii as a Viable Candidate for Human Trials". Journal of Fungi (Basel, Switzerland). 8 (8): 838. doi:10.3390/jof8080838. ISSN 2309-608X. Archived from the original on 8 December 2022. Retrieved 8 December 2022.

External links

External resources